NEW YORK (360Dx) — Swedish biopharmaceutical firm BioArctic announced today that it has partnered with Brain Biomarker Solutions (BBS) to develop new biomarkers and diagnostic methods for Alzheimer's disease.
Under the terms of the deal, BioArctic will work with BBS — a spinout of the University of Gothenburg — to identify and measure new blood- and cerebrospinal fluid-based biomarkers that can be used to diagnose Alzheimer's disease and monitor the effects of investigational treatments for the condition.
Among the biomarkers being studied under the collaboration are amyloid beta protofibrils — components of the amyloid beta plaques that characterize Alzheimer's disease and the target of BioArctic's Phase II drug candidate BAN2401.
BioArctic will provide its proprietary antibodies and regulatory know-how to the alliance, with BBS contributing Alzheimer's disease and diagnostics expertise. Each company will be responsible for its own costs and they will jointly own the rights to any resulting products. Revenues generated through out-licensing deals for technologies arising from the partnership will also be shared equally.
Additional terms were not disclosed.
"We are very pleased with this important collaboration, which in the long term can create a new business opportunity for BioArctic but also further improve the ability to develop new drugs for Alzheimer's disease," BioArctic CEO Gunilla Osswald said in a statement.